NADIM II Study: What is the Ideal Time for Surgery in Stage IIIA Lung Cancer?

Moreno, Beatriz Raboso; Viña, Jesus Isea de la; Gato-Díaz, Pedro; Jiménez-Fernández, Marta; Olaiz-Navarro, Beatriz

doi:10.1016/j.arbres.2022.08.014

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 24‐month PFS rates of patients in the combination therapy group and chemotherapy alone group were 66.6% and 42.3%, respectively. The median PFS was not reached in the combination therapy group, while the median PFS in the chemotherapy alone group was 18.3 months (HR = 0.48, 95% CI: 0.25–0.91, p = 0.025) [ 6 , 7 ]. The NADIM II study was also the first clinical study in which neoadjuvant chemotherapy showed OS benefits in patients with resectable IIIA‐B NSCLC, suggesting that perioperative immune neoadjuvant + adjuvant is expected to further improve the efficacy.…”

Section: Advances In Immunotherapy For Nsclcmentioning

confidence: 99%

Recent advances in immunotherapy for lung cancer

Wang

Zhou

2023

Cancer Innovation

View full text Add to dashboard Cite

Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy-based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

show abstract

Section: Advances In Immunotherapy For Nsclcmentioning

confidence: 99%